Iceland· IS-EU/1/14/980/010-011
Cosentyx
A secukinumab product containing secukinumabum inn, registered in Iceland by Novartis Europharm Limited*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Secukinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC10 (secukinumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Secukinumab · ATC L04AC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of secukinumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Secukinumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.03
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Secukinumabum INN
- Manufacturer
- Novartis Europharm Limited*
- Country
- Iceland (IS)
- ATC code
- L04AC10
- ATC class
- Secukinumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean4455762 ml x1 áfpenISK 195689
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
150 interactions on record for secukinumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Secukinumab · interactions on record
150 records
- 27 severe
- 116 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Secukinumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCOSENTYXNovartis Europharm Limited, Dublin
- BelgiumCosentyx 300 mgNovartis Europharm
- SwedenCosentyx 300 mg Injektionsvätska, lösning i förfylld injektionspennaNovartis Europharm Limited
- PolandCosentyxNovartis Europharm Limited
- SpainCOSENTYX 300 MG SOLUCION INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- NorwayCosentyxNovartis Europharm Limited (1)
- United StatesCOSENTYXNovartis Pharmaceuticals Corporation
- SwitzerlandCosentyx
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Cosentyx
- Norway · Cosentyx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd6dab3a-2a27-4836-8232-e9891e8e854c GET /v1/drugs/bd6dab3a-2a27-4836-8232-e9891e8e854c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltum lyfjapenna",
"source": "lyfjastofnun",
"atc_raw": "L04AC10",
"marketed": true,
"strength": "300 mg",
"ma_number": "EU/1/14/980/010-011",
"substance": "Secukinumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum og ónæmisfræði.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44155"
}See everything about secukinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.